Abbott Archives - Page 26 of 34 - Medical Design Sourcing

DTW Podcast: Earnhardt shares how Abbott shifted gears to counter pandemic; Grail still looks to upend oncology

Abbott’s medical devices EVP Lisa Earnhardt discusses the life science giant’s pivot during the COVID-19 pandemic.

In this week’s DeviceTalks Weekly Podcast, Abbott’s medical devices EVP Lisa Earnhardt explains how the life sciences giant pivoted during the pandemic. Earnhardt shares what programs were given greater priority when the lockdown’s impact became clear and why the company performed so well in one of its key businesses.

We also explore this week’s news that the FTC will oppose Illumina’s acquisition of Grail through interviews with Dr. Christopher Keir, vice president of medical affairs at Grail, and Vijay Kumar, senior managing director at Evercore ISI.

And, of course, Chris Newmarker, executive editor of MassDevice, delivers this week’s Newmarker’s Newsmakers, including news from Illumina, Grail, Corindus, Zimmer Biomet, BD, Medtronic and Abbott.

Final…

MedTech 100 roundup: Heading back to previous heights?

Although March brought on tough times for top stocks in the medtech industry, April is already showing signs of a rebound.

The year’s strong start, during which MassDevice‘s MedTech 100 index notched an all-time best of 110.96 points (Feb. 15) came to an end later that month and carried over into March, with the index hitting its lowest recent point on March 8 (102.16), marking a fall at a level not seen since October.

Even after a handful of slight improvements over the month of March, the industry never quite found its footing, ending the month below the 105-point mark.

The first week of April has already presented positive movement, though, with the industry rising to 106.26 points as the week ended on April 2, a 1.3% rise from the 104.87-point mark set the week prior on March 26.

Improvements highlight the secure position the industry has nestled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry…

DTW Podcast: Earnhardt shares how Abbott shifted gears to counter pandemic; Grail still looks to upend oncology

This week, we’ll talk with Lisa Earnhardt, executive vice president, medical devices at Abbott about how the life sciences giant pivoted during the pandemic.

Earnhardt shares what programs were given greater priority when the impact of the lockdown became clear and why the company performed so well in one of its key businesses.

We also explore this week’s news that the FTC will oppose Illumina’s acquisition of Grail.

First, we talk with Dr. Christopher Keir, vice president of medical affairs at Grail, about the great potential of the company’s diagnostic technologies. The interview was recorded last month prior to the FTC’s decision.

Then we talk to Vijay Kumar, senior managing director at Evercore ISI, about why the FTC is making a strong case to block the deal.

And, of course, Chris …

FDA authorizes use of over-the-counter COVID-19 tests for screening

The FDA announced today that it authorized several COVID-19 tests for over-the-counter use in asymptomatic screening.

Among the tests authorized were the BinaxNow Ag card from Abbott (which includes point-of-care screening), the Quidel Quick-View at-home test and the BD Veritor Plus system, which was authorized for POC screening with a prescription.

“BD is supporting the global efforts to return to normalcy as soon as possible, and this additional authorization for the BD Veritor system to be used in screening through serial testing of asymptomatic individuals is a large step forward,” BD life sciences president Dave Hickey said in a news release. “Frequent testing of individuals without symptoms will enable those with negative results to resume their normal school or work routines and will help to identify and isolate positive cases of COVID-19 as early as possible to prevent further spread.

“Screening through serial testing is a…

Abbott’s rapid COVID-19 self-test is now over-the-counter

The BinaxNow COVID-19 Ag Card [Image courtesy of Abbott]Abbott (NYSE:ABT) announced that it received FDA emergency use authorization (EUA) for over-the-counter use of its BinaxNOW COVID-19 test.

The new indication for the diagnostic allows individuals with or without symptoms to access the BinaxNOW COVID-19 Ag self test over the counter, without a prescription. The company plans to begin shipping to major food, drug and mass merchandiser retailers in the coming weeks and anticipates the test to be made available through some online stores, too, according to a news release.

Abbott Park, Ill.-based Abbott’s BinaxNOW test can be used on children as young as two years old when samples are collected by an adult, plus for all people aged 15 years or older. The rapid antigen test will come in a two-count box.

Those using the test will only need to perform a minimally invasive nasal swab, rather than a deep nasopharyngeal swab, with all materials required to …

4 innovative devices delivered through catheters

[Images from Boston Scientific, Abbott, Edwards Lifesciences and Medtronic]Physicians use catheters to deploy numerous life-saving devices across the healthcare realm, from cardiovascular to neurovascular.

They typically insert the thin, flexible tubes in a process called catheterization to deploy devices such as left ventricular assist devices (LVADs), transcatheter aortic valve replacements (TAVRs) and occluders to stop bleeding. The catheter industry is regularly innovating to keep up with the medtech industry’s growing demand for smaller devices for larger patient populations.

Throughout 2020, we saw a number of FDA clearances and approvals for catheter-based technologies, including ones designed for conditions renal denervation and heart failure. Just a few months into 2021, the FDA has approved catheter-based innovations by two major medtech companies. Two others developed for high-risk patients are worth revisiting.

Next >>

4 innovative devices delivered through catheters

[Images from Boston Scientific, Abbott, Edwards Lifesciences and Medtronic]

Physicians use catheters to deploy numerous life-saving devices across the healthcare realm, from cardiovascular to neurovascular.

They typically insert the thin, flexible tubes in a process called catheterization to deploy devices such as left ventricular assist devices (LVADs), transcatheter aortic valve replacements (TAVRs) and occluders to stop bleeding. The catheter industry is regularly innovating to keep up with the medtech industry’s growing demand for smaller devices for larger patient populations.

Throughout 2020, we saw a number of FDA clearances and approvals for catheter-based technologies, including ones designed for conditions renal denervation and heart failure. Just a few months into 2021, the FDA has approved catheter-based innovations by two major medtech companies. Two others developed for high-risk patients a…

8 medical device companies that beat the COVID-19 pandemic and prospered

[Image from unsplash.com]Some medical device businesses not only survived the COVID-19 pandemic but actually thrived — with many producing the medtech needed to fight the coronavirus’s spread.

Medical Design & Outsourcing recently analyzed financials for 20 of the largest medical device businesses in the world. Not only was revenue only slightly down for the 20 during 2020, but it was actually up for eight of the 20 companies.

For many of the eight companies that saw sales increase, there was a common theme: They pivoted their focus to the diagnostics imaging and personal protective equipment needed to against COVID-19.

“We had different kinds of companies that were able to benefit on some level from COVID and shutdowns,” Richard Newitter, senior research analyst at SVB Leerink, told MDO.

Overall, medtech sales declined in Q1 and Q2 but then bounced back in a V-shaped recovery for the rest of the year, according to Newitter “It plateaued and actu…

8 medical device companies that beat the COVID-19 pandemic and prospered

[Image from unsplash.com]

Some medical device businesses not only survived the COVID-19 pandemic but actually thrived — with many producing the medtech needed to fight the coronavirus’s spread.

Medical Design & Outsourcing recently analyzed financials for 20 of the largest medical device businesses in the world. Not only was revenue only slightly down for the 20 during 2020, but it was actually up for eight of the 20 companies.

For many of the eight companies that saw sales increase, there was a common theme: They pivoted their focus to the diagnostics imaging and personal protective equipment needed to against COVID-19.

“We had different kinds of companies that were able to benefit on some level from COVID and shutdowns,” Richard Newitter, senior research analyst at SVB Leerink, told MDO.

Overall, medtech sales declined in Q1 and Q2 but then bounced back in a V-shaped recovery fo…

How big medtech fared during a year of COVID-19

[Image from Unsplash]Despite numerous challenges, the medtech industry showed itself to be fairly recession-proof in 2020, according to a Medical Design & Outsourcing/MassDevice analysis of financials.

Annual reports recently released by 20 of the world’s largest medical device companies showed only a slight dip in revenue during 2020 — a year in which medtech held the front lines against the COVID-19 pandemic. Employment was also up slightly amongst the top earners, while R&D spending held its own.

The 20 companies included in the MDO analysis include 3M Healthcare, Abbott (medical device segment), Alcon, Align Technology, Baxter, Boston Scientific, Danaher (life sciences and diagnostics segment), Dentsply Sirona, Edwards Lifesciences, GE Healthcare, Henry Schein, Intuitive Surgical, Johnson & Johnson (medical device segment), Medline Industries, Owens & Minor, Royal Philips, Smith+Nephew, Stryker, Teleflex and Zimmer Biomet.

Get the full s…

How big medtech fared during a year of COVID-19

[Photo from Unsplash]

Despite numerous challenges, the medtech industry showed itself to be fairly recession-proof in 2020, according to a Medical Design & Outsourcing analysis of financials.

Annual reports recently released by 20 of the world’s largest medical device companies showed only a slight dip in revenue during 2020 — a year in which medtech held the front lines against the COVID-19 pandemic. Employment was also up slightly amongst the top earners, while R&D spending held its own.

The 20 companies included in the MDO analysis include 3M Healthcare, Abbott (medical device segment), Alcon, Align Technology, Baxter, Boston Scientific, Danaher (life sciences and diagnostics segment), Dentsply Sirona, Edwards Lifesciences, GE Healthcare, Henry Schein, Intuitive Surgical, Johnson & Johnson (medical device segment), Medline Industries, Owens & Minor, Royal Philips, Smith+Nephew, …

St. Jude Medical wins patent spat over catheterization method

St. Jude Medical has won a patent dispute over the method for using a double catheter in heart failure patients.

Niazi Licensing’s patent, issued in 2003 for the double catheter system, describes it as better suited for “use in the coronary sinus, especially in patients suffering from congestive heart failure,” according to the order issued this week by a federal court judge in Minnesota.

Get the full story on our sister site, Medical Tubing + Extrusion.